Patents Assigned to TOKUSHIMA UNIVERSITY
  • Patent number: 11453931
    Abstract: The present invention relates to a medical Au—Pt—Pd alloy including Au, Pt, Pd, and inevitable impurities. The alloy has an alloy composition inside a polygon (A1-A2-A3-A4-A5-A6) surrounded by straight lines connected at point A1 (Au: 37.9 atom %, Pt: 0.1 atom %, and Pd: 62 atom %), point A2 (Au: 79.9 atom %, Pt: 0.1 atom %, and Pd: 20 atom %), point A3 (Au: 79.9 atom %, Pt: 20 atom %, and Pd: 0.1 atom %), point A4 (Au: 69.9 atom %, Pt: 30 atom %, and Pd: 0.1 atom %), point A5 (Au: 49 atom %, Pt: 30 atom %, and Pd: 21 atom %), and point A6 (Au: 39 atom %, Pt: 40 atom %, and Pd: 21 atom %) in a Au—Pt—Pd ternary state diagram. The metal structure of the alloy is optimized, and the metal structure is close to a single-phase structure, and has little precipitation of a Au-rich phase and a Pt-rich phase different in composition from a mother phase.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: September 27, 2022
    Assignees: TANAKA KIKINZOKU KOGYO K.K., TOKUSHIMA UNIVERSITY
    Inventors: Michimasa Okubo, Kenji Goto, Kunihiro Tanaka, Kojiro Shiraishi, Kunihiro Shima, Yuya Kato, Kenichi Hamada, Eiichi Honda, Emi Takegawa
  • Publication number: 20220257676
    Abstract: [Problem] The purpose of the present invention is to provide a novel technology capable of regulating female hormone secretion. [Solution] Provided is an agent for regulating female hormone secretion, which contains the lactobacillus strain Lactobacillus gasseri strain CP2305 (accession No.: FERM PB-11331), a treated product of said lactobacillus strain, or extracts thereof.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 18, 2022
    Applicants: Asahi Group Holdings, Ltd., Tokushima University
    Inventors: Daisuke SAWADA, Shigeru FUJIWARA, Tomonori SUGAWARA, Kazuhito ROKUTAN, Kensei NISHIDA, Yuki KUWANO
  • Publication number: 20220227887
    Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.
    Type: Application
    Filed: June 10, 2020
    Publication date: July 21, 2022
    Applicants: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITY
    Inventors: Taku OKAZAKI, Daisuke SUGIURA, II-mi OKAZAKI, Shiro SHIBAYAMA
  • Publication number: 20220220234
    Abstract: The present invention provides a vinyl alcohol-amino acid ester copolymer that is excellent in properties such as cell culture properties, biocompatibility, antibacterial properties, and solubility in organic solvents, and is applicable to the medical field, the biomaterial field, and the agricultural field (medical and life science fields). Provided is a vinyl alcohol-amino acid ester copolymer including a unit represented by the following formula (1) and a unit represented by the following formula (2): where, in the formula (2), R1 represents a hydrocarbon group that may optionally have a substituent, R2 and R3 each independently represent a hydrogen atom or a hydrocarbon group, and R1 and R2, or R2 and R3, may optionally be bonded together to form a cyclic structure.
    Type: Application
    Filed: May 8, 2020
    Publication date: July 14, 2022
    Applicants: SEKISUI CHEMICAL CO., LTD., TOKUSHIMA UNIVERSITY
    Inventors: Yohei NISHIMURA, Risa YAMAZAKI, Koichi UTE, Miyuki OSHIMURA, Tomohiro HIRANO, Ryo KAGITANI
  • Publication number: 20220213576
    Abstract: The present invention relates to a medical Au—Pt—Pd alloy including Au, Pt, Pd, and inevitable impurities. The alloy has an alloy composition inside a polygon (A1-A2-A3-A4-A5-A6) surrounded by straight lines connected at point A1 (Au: 37.9 atom %, Pt: 0.1 atom %, and Pd: 62 atom %), point A2 (Au: 79.9 atom %, Pt: 0.1 atom %, and Pd: 20 atom %), point A3 (Au: 79.9 atom %, Pt: 20 atom %, and Pd: 0.1 atom %), point A4 (Au: 69.9 atom %, Pt: 30 atom %, and Pd: 0.1 atom %), point A5 (Au: 49 atom %, Pt: 30 atom %, and Pd: 21 atom %), and point A6 (Au: 39 atom %, Pt: 40 atom %, and Pd: 21 atom %) in a Au—Pt—Pd ternary state diagram. The metal structure of the alloy is optimized, and the metal structure is close to a single-phase structure, and has little precipitation of a Au-rich phase and a Pt-rich phase different in composition from a mother phase.
    Type: Application
    Filed: September 24, 2020
    Publication date: July 7, 2022
    Applicants: TANAKA KIKINZOKU KOGYO K.K., TOKUSHIMA UNIVERSITY
    Inventors: Michimasa OKUBO, Kenji GOTO, Kunihiro TANAKA, Kojiro SHIRAISHI, Kunihiro SHIMA, Yuya KATO, Kenichi HAMADA, Eiichi HONDA, Emi TAKEGAWA
  • Patent number: 11377506
    Abstract: The present invention provides a vinyl alcohol-vinyl acetate copolymer having excellent solubility and capable of providing a film having high flexibility, high mechanical strength, and high adhesion, and a method for producing a vinyl alcohol-vinyl acetate copolymer. Provided is a vinyl alcohol-vinyl acetate copolymer including a unit of vinyl alcohol and a unit of vinyl acetate, the vinyl alcohol-vinyl acetate copolymer having a triad unit chain ratio TOO of 7.5 or less, where the triad unit chain ratio TOO is obtained using the following formula (1): [ Math .
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: July 5, 2022
    Assignees: TOKUSHIMA UNIVERSITY, SEKISUI CHEMICAL CO., LTD.
    Inventors: Koichi Ute, Tomohiro Hirano, Miyuki Oshimura, Yasunari Kusaka, Yohei Nishimura, Misaki Senoo
  • Publication number: 20220098256
    Abstract: The present invention provides peptides containing the BIG3 polypeptide-binding site in a PHB2 polypeptide, which inhibit the binding between a PHB2 polypeptide and a BIG3 polypeptide, and pharmaceutical compositions containing the peptide. The peptides of the present invention have the ability to bind not to PHB2, whose expression is found in organs throughout the human body, but to BIG3, which is a protein highly expressed specifically in particularly estrogen receptor-positive cancer, and have excellent growth suppressive effects on BIG3-positive cancer cells. Accordingly, the peptides of the present invention are useful as therapeutic agents for breast cancer which can avoid expression of side effects.
    Type: Application
    Filed: November 28, 2019
    Publication date: March 31, 2022
    Applicants: TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE, iNC.
    Inventors: TOYOMASA KATAGIRI, TETSURO YOSHIMARU, AKIRA OTAKA, TAKASHI MIYAMOTO, YASUHIDE OKAMOTO
  • Publication number: 20220042140
    Abstract: The present invention relates to a medical Au—Pt—Pd alloy including Au, Pt, Pd, and inevitable impurities. The Au—Pt—Pd alloy has an alloy composition inside a polygon (A1-A2-A3-A4) surrounded by straight lines connected at point A1 (Au: 53 atom %, Pt: 4 atom %, and Pd: 43 atom %), point A2 (Au: 70 atom %, Pt: 4 atom %, and Pd: 26 atom %), point A3 (Au: 69.9 atom %, Pt: 30 atom %, and Pd: 0.1 atom %), and point A4 (Au: 49.9 atom %, Pt: 50 atom %, and Pd: 0.1 atom %) in a Au—Pt—Pd ternary state diagram. In a metal structure of the alloy, at least one of a Au-rich phase and a Pt-rich phase is distributed, and the total of the area ratio of the Au-rich phase and the area ratio of the Pt-rich phase is 1.5% or more and 25.4% or less.
    Type: Application
    Filed: September 24, 2020
    Publication date: February 10, 2022
    Applicants: TANAKA KIKINZOKU KOGYO K.K., TOKUSHIMA UNIVERSITY
    Inventors: Michimasa OKUBO, Kenji GOTO, Kunihiro TANAKA, Kojiro SHIRAISHI, Kunihiro SHIMA, Yuya KATO, Kenichi HAMADA, Eiichi HONDA, Emi TAKEGAWA
  • Publication number: 20220025051
    Abstract: An immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 27, 2022
    Applicants: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITY
    Inventors: Taku OKAZAKI, Daisuke SUGIURA, Takeo MAEDA, Shiro SHIBAYAMA
  • Patent number: 11124881
    Abstract: The objective of the present invention is to provide a hydrophilic metal surface treatment agent by which a water-repellent property can be given to a metal surface with suppressing a corrosion and a discolorment of the metal, a method for treating a surface of a metal by using the hydrophilic metal surface treatment agent, a synthetic intermediate compound of a branched glycerol derivative as an active ingredient of the hydrophilic metal surface treatment agent, and a method for efficiently producing the synthetic intermediate compound. The hydrophilic metal surface treatment agent of the present invention is characterized in comprising the branched glycerol derivative represented by the following formula (I) as an active ingredient. wherein R1 is a hydrocarbon group having a carbon number of 10 or more and 30 or less, X is S or a carbonyl group, Y is an n+1 valent linker group, n is an integer of 1 or more and 5 or less.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: September 21, 2021
    Assignees: CHEMICAL DENSHI CO., LTD., TOKUSHIMA UNIVERSITY
    Inventors: Shoichi Yamada, Toshio Hyuga, Hisao Nemoto
  • Publication number: 20210253522
    Abstract: The present invention is a heterocycle-containing amino acid compound represented by a general formula (1): wherein R1 and R2 are identical with or different from each other, and each represent a hydrogen atom or a carboxy-protecting group; R3 represents a carboxyl group or a hydroxyl group; and n is 1 or 2, or a salt thereof.
    Type: Application
    Filed: August 22, 2019
    Publication date: August 19, 2021
    Applicants: TOKUSHIMA UNIVERSITY, AICHI STEEL CORPORATION
    Inventors: Kosuke NAMBA, Motofumi SUZUKI, Akane MERA
  • Patent number: 11091517
    Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: August 17, 2021
    Assignees: TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE, INC.
    Inventors: Toyomasa Katagiri, Tetsuro Yoshimaru, Takashi Miyamoto, Yasuhide Okamoto
  • Publication number: 20210246560
    Abstract: The objective of the present invention is to provide a hydrophilic metal surface treatment agent by which a water-repellent property can be given to a metal surface with suppressing a corrosion and a discolorment of the metal, a method for treating a surface of a metal by using the hydrophilic metal surface treatment agent, a synthetic intermediate compound of a branched glycerol derivative as an active ingredient of the hydrophilic metal surface treatment agent, and a method for efficiently producing the synthetic intermediate compound. The hydrophilic metal surface treatment agent of the present invention is characterized in comprising the branched glycerol derivative represented by the following formula (I) as an active ingredient. wherein R1 is a hydrocarbon group having a carbon number of 10 or more and 30 or less, X is S or a carbonyl group, Y is an n +1 valent linker group, n is an integer of 1 or more and 5 or less.
    Type: Application
    Filed: June 4, 2020
    Publication date: August 12, 2021
    Applicants: CHEMICAL DENSHI CO., LTD., Tokushima University
    Inventors: Shoichi YAMADA, Toshio HYUGA, Hisao NEMOTO
  • Patent number: 11000572
    Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 11, 2021
    Assignee: TOKUSHIMA UNIVERSITY
    Inventors: Akihito Yamamoto, Minoru Ueda, Kohki Matsubara, Akio Suzumura, Koichi Furukawa, Yoshihiro Matsushita, Hirotaka Wakayama, Nobunori Takahashi, Shin Tsunekawa, Takako Izumoto
  • Patent number: 10976240
    Abstract: A concentration measurement device for measuring the concentration of a measured fluid within a measurement cell by detecting transmitted light that has passed through the measurement cell having a light incidence window and a light emission window disposed opposing to each other, comprising a reflected-light detector for detecting reflected light of the light incidence window.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 13, 2021
    Assignees: TOKUSHIMA UNIVERSITY, FUJIKIN INCORPORATED
    Inventors: Yoshihiro Deguchi, Masaaki Nagase, Michio Yamaji, Nobukazu Ikeda, Kouji Nishino, Masayoshi Kawashima, Kazuteru Tanaka
  • Patent number: 10928303
    Abstract: A concentration measuring device includes a measuring cell having a flow passage and a translucent window, a light source for emitting light to the measuring cell through the window, a reflective member for reflecting light propagating through the measuring cell to the window, a light detector for detecting the light exiting from the window, a calculation part for calculating the concentration of the fluid on the basis of a detection signal from the light detector, and an optical device for guiding the light from the light source to the window and guiding the light from the window to the light detector.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 23, 2021
    Assignees: TOKUSHIMA UNIVERSITY, FUJIKIN INCORPORATED
    Inventors: Yoshihiro Deguchi, Takashi Fukawa, Taiki Hattori, Masaaki Nagase, Kazuteru Tanaka, Kouji Nishino, Nobukazu Ikeda
  • Publication number: 20200392464
    Abstract: An object of the present invention is to provide a method for producing insulin-producing cells having sufficient glucose responsiveness from mesenchymal stem cells, an insulin-producing cell having sufficient glucose responsiveness, a cell structure containing the insulin-producing cell, and a pharmaceutical composition.
    Type: Application
    Filed: May 8, 2020
    Publication date: December 17, 2020
    Applicants: FUJIFILM Corporation, Tokushima University
    Inventors: Kentaro NAKAMURA, Mitsuo SHIMADA, Tetsuya IKEMOTO
  • Publication number: 20200347165
    Abstract: The present invention provides a vinyl alcohol-vinyl acetate copolymer having excellent solubility and capable of providing a film having high flexibility, high mechanical strength, and high adhesion, and a method for producing a vinyl alcohol-vinyl acetate copolymer. Provided is a vinyl alcohol-vinyl acetate copolymer including a unit of vinyl alcohol and a unit of vinyl acetate, the vinyl alcohol-vinyl acetate copolymer having a triad unit chain ratio TOO of 7.5 or less, where the triad unit chain ratio TOO is obtained using the following formula (1): [ Math .
    Type: Application
    Filed: November 14, 2018
    Publication date: November 5, 2020
    Applicants: TOKUSHIMA UNIVERSITY, SEKISUI CHEMICAL CO., LTD.
    Inventors: Koichi UTE, Tomohiro HIRANO, Miyuki OSHIMURA, Yasunari KUSAKA, Yohei NISHIMURA, Misaki SENOO
  • Publication number: 20200255474
    Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.
    Type: Application
    Filed: July 18, 2018
    Publication date: August 13, 2020
    Applicants: TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE, INC
    Inventors: Toyomasa KATAGIRI, Tetsuro YOSHIMARU, Takashi MIYAMOTO, Yasuhide OKAMOTO
  • Patent number: 10732099
    Abstract: A gas analysis device includes a laser light source configured to output a laser beam, an irradiation unit configured to irradiate a measurement region including measurement target gas with the laser beams in plural directions, plural photoreceivers each configured to receive a laser beam having passed through the measurement region and output an electric signal according to intensity of the received laser beam, and an analyzer configured to analyze the physical state of the measurement target gas based on the electric signal output from each photoreceiver. The analyzer sets a function (e.g. two-dimensional polynomial f(X,Y)) representing the physical state (e.g. concentration, temperature) of the target gas at least in the measurement region, and measures the physical state of the target gas by determining a coefficient of each of terms included in the function based on a measured value obtained from the electric signal output from the photoreceiver.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: August 4, 2020
    Assignee: Tokushima University
    Inventor: Yoshihiro Deguchi